EUCTR2015-002963-40-ES进行中(未招募)不适用
Impact of treatment with Dapagliflozin (SGLT2 inhibitor) in metabolic control and glycemic pattern in type 1 diabetic patients - IDAPADM1
Dra Cristina Avendaño Sola0 个研究点开始时间: 2015年7月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中(未招募)
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •(1)Women or men aged 18-55 years od oldf at the time of completion of the informed consent.
- •(2)Written informed consent in conformity with local legislation obtaines before the performance of any procedure.
- •(3)Patients with a diagnosis of type 1 diabetes mellitus (Diabetes diagnosed before 30 years old in a patient without overweight/obesity or diabetes diagnosed before 45 years old with evidence of positive pancreatic autoantibodies)
- •(4)Treatment with multiple daily dose of insulin (1-2 injections of Glargina/Detemir with 3 injections of rapid insulin analogues) or continous subcutaneous insulin infusion therapy
- •(5)HbA1c greater than 7% in at least two consecutive blood tests (separated at least for 3 months) performed during the past 6 months previous to the beginning of the study
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 57
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •(1)Inability to give inform consent in the absence of a legal guardian
- •(2)Pregnancy or lactation
- •(3)If there are any clijnical, biochemical, cognitive, social or psycosocial factors (considered by the investigador) that could negative influence the study or patient.
- •(4)Liver disease (history of chronic liver disease or alteration in liver function tests: AST, ALT, bilirrubin, GGT)
- •(5)Renal failure (MDRD < 60 ml/min)
- •(6)History of multiple urinary tract or mycotic genital infections
- •(7)History of baldder cancer
- •(8)History of electrolyte disorders (SIADH, insipid diabetes, hyponatremia)
- •(9)Treatment with loop diuretics
- •(10)Haven received any drug under investigation, including antivirals, during the previous 6 months of starting the study.
研究者
相似试验
招募中
不适用
ong-term effects of dapagliflozin, a SGLT2 inhibitor, on glucose metabolism in patients with type 2 diabetes mellitustype 2 diabetes mellitusJPRN-UMIN000026042Kurume University School of Medicine300
尚未招募
不适用
Effect of SGLT2 inhibitor, Dapagliflozin combined with or without metformin on body composition in patients with type 2 diabetestype 2 diabetes mellitusJPRN-UMIN000030446St. Marianna University School of Medicine54
已完成
1 期
Dapagliflozin Effects on HypoglycemiaType1 Diabetes MellitusNCT03704818University of California, San Diego22
尚未招募
Unknown
Evaluation of the effects of Dapaglifozin on liver on patients with Type 2 Diabetes Mellitus and Metabolic liver diseaseCTRI/2023/03/050799Department of medicine Jawaharlal Nehru medical college and hospital AMU Aligarh
已完成
不适用
Effect of Dapagliflozin in patients with type 2 daibetes mellitusType 2 diabetes mellitusJPRN-UMIN000014922Iwasaki Naika Clinic50
